1. High long-term persistence to evolocumab treatment regimens in European clinical practice: analysis of the HEYMANS registry. (3rd October 2022) Authors: Ray, K K; Perrone-Filardi, P; Ebenbichler, C; Vogt, A; Bridges, I; Sibartie, M; Dhalwani, N N Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia. (3rd October 2022) Authors: Wiegman, A; Ruzza, A; Hovingh, G K; Santos, R D; Mach, F; Stefanutti, C; Luirink, I; Bridges, I; Wang, B; Bhatia, A K; Raal, F J; Kastelein, J J P; Gaudet, D Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry. (3rd October 2022) Authors: Ray, K K; Perrone-Filardi, P; Ebenbichler, C; Vogt, A; Bridges, I; Sibartie, M; Dhalwani, N N Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Evaluation of prognostic risk models for postoperative pulmonary complications in adult patients undergoing major abdominal surgery: a systematic review and international external validation cohort study. Issue 7 (July 2022) Authors: Kouli, O; Murray, V; Bhatia, S; Cambridge, WA; Kawka, M; Shafi, S; Knight, SR; Kamarajah, SK; McLean, KA; Glasbey, JC; Khaw, RA; Ahmed, W; Akhbari, M; Baker, D; Borakati, A; Mills, E; Thavayogan, R; Yasin, I; Raubenheimer, K; Ridley, W Journal: Lancet Issue: Volume 4:Issue 7(2022) Page Start: e520 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study. (25th November 2020) Authors: Ray, K.K; Bruckert, E; Van Hout, B; Feudjo Tepie, M; Bridges, I; Sibartie, M Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Evolocumab use in Europe: clinical guidelines vs. reimbursement thresholds – results from the HEYMANS study. (14th October 2021) Authors: Ray, K K; Bruckert, E; Filardi, P; Ebenbichler, C; Vogt, A; Bridges, I; Sibartie, M; Dhalwani, N N Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. What potential risk reduction could be achieved with evolocumab treatment? A simulation based on observational data from a cohort of users in 10 European countries. (25th November 2020) Authors: Ray, K.K; Bridges, I; Bruckert, E; Van Hout, B; Sibartie, M; Villa, G Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Potential cardiovascular risk reduction with evolocumab in the real world: a simulation in patients with a history of myocardial infarction from the HEYMANS register. (14th October 2021) Authors: Ray, K; Bridges, I; Bruckert, E; Perrone-Filardi, P; Annemans, L; Sibartie, M; Dhalwani, N; Villa, G Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗